Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout on July 23, 2026 ALK gene Antineoplastic Agents Approved neladalkib Non-Small Cell Lung Carcinoma Nuvalent ROS1 gene SmithKline Beecham United States Food and Drug Administration zidesamtinib +
GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade on June 10, 2026 acquisition ALK Inhibitor Inhibitor Malignant neoplasm of lung neladalkib Neoplasms Nuvalent ROS1 gene SmithKline Beecham zidesamtinib +
GSK to Acquire Nuvalent and Its Two Cancer Drugs Under FDA Review for $10.6 Billion on June 09, 2026 acquisition Malignant neoplasm of lung neladalkib Non-Small Cell Lung Carcinoma Nuvalent Oncology drugs Review [Publication Type] SmithKline Beecham United States Food and Drug Administration zidesamtinib +
Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer on November 17, 2025 ALK Inhibitor ALKOVE-1 trial Clinical Trials CNS activity Frequency of Responses Lorbrena lorlatinib neladalkib Non-Small Cell Lung Carcinoma Nuvalent Phase 1/2 data United States Food and Drug Administration +